1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals, Inc.

SNNAQ
Sienna Biopharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
3,091.00Market Cap
Sienna Biopharmaceuticals, Inc.
SNNAQ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
TTM
FRC
- -
- -
- -
- -
- -
Revenue per Share
-0.99
-1.86
-5.19
-3.59
-1.8
Basic EPS, GAAP
-0.88
-1.57
-4.24
-3.02
-2.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
-1.25
-3.1
-8.82
-7.79
-7.06
Book Value per Share
-1.43
-7.81
3.3
-1.47
-0.01
Tangible Book Value per Share
11
11
10
20
27
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
-11
-21
-51
-73
-48
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
5
1
69
26
18
Working Capital
- -
- -
- -
30
- -
LT Debt
4
22
91
27
23
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
ST Debt
- -
- -
- -
LT Borrowings
29
29
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
31
31
Market Capitalization
50
21
5

Working Capital

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
Total Current Assets
59
51
20
Cash, Cash Equivalents & STI
57
49
11
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
22
21
1
Payables & Accruals
8
7
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-70.85%
Free Cash Flow
- -
- -
49.52%
Net Income, GAAP
- -
- -
45.36%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
-0.89
-0.65
-1.12
-0.56
-5.19
2018
-0.85
-1
-0.82
-0.93
-3.59
2019
-0.67
-0.27
-0.13
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
Similar Companies
Advaxis, Inc. (ADXSD)
Telix Pharmaceuticals Limited (TLPPF)
Gene Biotherapeutics, Inc. (CRXM)
Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
Galecto, Inc. (DMRA)
Open Orphan Plc (ORPH.L)
Business
Sienna Biopharmaceuticals, Inc. (SNNAQ) develops and commercializes non-invasive dermatological therapies focused on addressing unmet needs in aesthetic and medical skin conditions. The company offers SNAP-201, a topical product utilizing the proprietary SNAP (Sodium Channel Antagonist Peptide) technology platform for non-invasive hyperhidrosis treatment; SNAP-301 for clearance of common warts; and other pipeline candidates targeting androgenetic alopecia and facial erythema associated with rosacea. Founded in 2016 and headquartered in Westlake Village, California, Sienna operates primarily in the United States within the biotechnology and dermatology sectors, serving patients and healthcare providers through clinical-stage product development. [ from previous searches, noting limited recent updates; company website confirms core pipeline as of last available data] Recent major developments for Sienna Biopharmaceuticals include its delisting from Nasdaq and trading under the SNNAQ ticker following financial restructuring efforts amid clinical setbacks; no significant partnerships, acquisitions, funding rounds, or new product launches reported in the past 1-2 years, with the company focusing on stabilizing operations post-2023 pipeline challenges.

Company News

APIChat

  • defenseworld.net

    Analyzing Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) & HCW Biologics (NASDAQ:HCWB)